TouchRESPIRATORY got the opportunity to catch up with Dr Dermot Ryan (Asthma UK Centre for Applied Research, The University of Edinburgh, Edinburgh, Scotland) around his presentation on ‘Respiratory Allergy: The Role of Immunotherapy in Primary Care.’ which was presented at The IPCRG 10th World Conference, 6-8 May, 2021.
- According to current IPCRG guidelines, for which patients is allergen immunotherapy recommended? (0:27)
- Could you give us a brief overview of the methods of allergen immunotherapy that are currently used in primary care? (2:27)
- What factors predict a successful response to allergen immunotherapy? (4:07)
- How do you expect the role of allergen immunotherapy in primary care to develop in the future? (5:08)
Disclosures: Dermot Ryan has nothing to disclose in relation to this video
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of IPCRG 2021 (Virtual).
Share this Video
Related Videos In Allergy
Management of Non-steroidal Anti-inflammatory Drug-exacerbated Respiratory Disease
Talking abstract delivered by Dr Mark Arnold (Emory University School of Medicine, Atlanta, GA, USA) for the paper: Arnold M, Kuruvilla M and Levy JM. Management of Non-steroidal Anti-inflammatory Drug-exacerbated Respiratory Disease. touchREVIEWS in Respiratory & Pulmonary Diseases. 2021;6(1):Online ahead of journal publication.
David Fleischer: Updates in Peanut Allergy Treatment
TouchRESPIRATORY got the opportunity to catch up with Dr. David Fleischer (Children’s Hospital Colorado, Aurora, CO, USA) to discuss the current available therapies and future of the treatment paradigm for peanut allergy. Questions How has the approval of Palforzia impacted the treatment paradigm for peanut allergies? (0:14) What questions remain unanswered regarding oral immunotherapies and […]
Frédéric de Blay, EAACI 2021: Anti-Fel D 1 Monoclonal Antibodies Reduce the Rate of Early Asthma Responses
touchRESPIRATORY joins Professor Frédéric de Blay (University Hospital of Strasbourg, Strasbourg, France) at EAACI 2021 to discuss the results of a phase 2, randomised, double-blind, placebo-controlled study of anti-Fel d 1 monoclonal antibodies in reducing the rate of early asthma responses, chest symptoms and rescue medication use in cat-allergic subjects with mild asthma for up […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!